XOMA Royalty (NASDAQ:XOMA) Given Buy Rating at HC Wainwright

XOMA Royalty (NASDAQ:XOMA)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $97.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 237.27% from the company’s previous close.

A number of other equities analysts have also weighed in on the company. Benchmark restated a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. TD Cowen raised XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. UBS Group set a $76.00 price target on XOMA Royalty in a research report on Tuesday, December 9th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research note on Tuesday, February 24th. Finally, Zacks Research lowered XOMA Royalty from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $61.60.

XOMA Royalty Price Performance

XOMA stock opened at $28.76 on Friday. The firm has a 50 day moving average of $26.11 and a 200-day moving average of $30.48. The firm has a market capitalization of $356.05 million, a P/E ratio of 19.70 and a beta of 0.86. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07.

XOMA Royalty (NASDAQ:XOMA) last posted its earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.16. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.40%. The business had revenue of $13.76 million for the quarter, compared to analyst estimates of $11.13 million. As a group, sell-side analysts predict that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Opaleye Management Inc. grew its stake in shares of XOMA Royalty by 14.7% during the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock valued at $7,780,000 after buying an additional 37,503 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in XOMA Royalty during the 4th quarter valued at about $237,000. Panagora Asset Management Inc. grew its position in XOMA Royalty by 24.2% during the 4th quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock worth $564,000 after acquiring an additional 4,135 shares during the last quarter. Barclays PLC increased its stake in XOMA Royalty by 12.1% in the 4th quarter. Barclays PLC now owns 14,822 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 1,598 shares during the period. Finally, State Street Corp increased its stake in XOMA Royalty by 4.7% in the 4th quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock worth $4,651,000 after purchasing an additional 7,873 shares during the period. 95.92% of the stock is owned by institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.